← All trials
NCT03968445
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 17, 2019
- Primary completion
- Oct 24, 2024
- Completion date
- Jul 24, 2025
- First posted
- May 30, 2019
- Last posted
- Aug 21, 2023
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Alabama, BirminghamLead sponsor
- University of Alabama, BirminghamReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.